000			05436nam a22004335i 4500
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
999			_c107926 _d107926 _x1
001			107926
003			DE-He213
005			20240627104954.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			181110s2018 gw | s |||| 0|eng d
020			_a9783319785387
024	7		_a10.1007/978-3-319-78538-7 _2doi
040			_bspa _dES-MaUEC
050		4	_aQR177 2018 EB
245	1	0	_aAntimicrobial Resistance in the 21st Century _cedited by I. W. Fong, David Shlaes, Karl Drlica.
250			_a2nd ed. 2018.
264		1	_aCham _bSpringer International Publishing : _bImprint: Springer _c2018.
300			_a1 recurso en línea ( XVIII, 775 páginas 106 ilustraciones, 74 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	1		_aEmerging Infectious Diseases of the 21st Century
490			_aMedicine (Springer-11650)
505	0		_aChapter1: Introduction : Coordinated Global Action is Needed to Combat Antimicrobial Resistance -- Part I: Examples of Resistance -- Chapter2: Antimicrobial Resistance Among Streptococcus pneumoniae -- Chapter3: Emergence of MRSA in the Community -- Chapter4: Resistance of Gram-negative Bacilli to Antimicrobials -- Chapter5: Drug Resistance in Tuberculosis -- Chapter6: Anaerobic Bacteria: Antimicrobial Susceptibility Testing and Resistance Patterns -- Chapter7: Clinical Significance and Biologic Basis of HIV Drug Resistance -- Chapter8: Resistance of Herpesviruses to Antiviral Agents -- Chapter9: Heteroresistance: A Harbinger of Future Resistance -- Part II: Biology of Resistance -- Chapter10: Epidemiology of Bacterial Resistance -- Chapter11: Transmissible Antibiotic Resistance -- Chapter12: Antibiotics and Resistance in the Environment -- Chapter13: Phenotypic Tolerance and Bacterial Persistence -- Chapter14: Staphylococcus aureus Adaptation During Infection -- Chapter15: Bacterial Signal Transduction Systems in Antimicrobial Resistance -- Chapter16: Fluoroquinolone Interactions with Bacterial Type II Topoisomerases and Target-mediated Drug Resistance -- Part III: Finding New Antimicrobials -- Chapter17: Natural Products in Antibiotic Discovery -- Chapter18: The New vs. Old Target Debate For Drug Discovery -- Chapter19: Non-quinolone Topoisomerase Inhibitors -- Chapter20: Antimicrobial-Mediated Bacterial Suicide -- Chapter21: PK/PD-based Prediction of "Anti-mutant" Antibiotic Exposures Using In Vitro Dynamic Models -- Part IV: Bringing Compounds to Market -- Chapter22: The Role of Pharmacometrics in the Development of Antimicrobial Agents -- Chapter23: New Regulatory Pathways for Antibacterial Drugs -- Chapter24: Economic Incentives for Antibacterial Drug Development: Alternative Market Structures to Promote Innovation.
520			_a Antimicrobial resistance is now a general problem. Many of us have elderly relatives who died from a drug-resistant infection, and some of us have suffered from a resistant urinary infection that likely came from intestinal bacteria following antibiotic consumption. Antimicrobial Resistance in the 21st Century provides a broad introduction to the subject in which the situation with problematic pathogens is detailed, the biology of resistance is described, and gaining approval for new antibiotics is discussed. Some topics are immediately practical, such as watching for resistant pathogen sub-populations in cultures taken from patients; other topics point to future research efforts that may lead to new antimicrobials and ways to stimulate the action of existing ones. Overall, Antimicrobial Resistance in the 21st Century provides an update for physicians, serves as a starting point for graduate students interested in solving the resistance problem, and may serve as a text for a course on resistance. Lay readers familiar with microbiology will gain an appreciation for a medical issue that promises to be one of the most important of our time. Ignatius Fong, Department of Medicine, University of Toronto Series Editor - Emerging Infectious Diseases of the 21st Century David Shlaes, Founder, Anti-Infectives Consulting Editor - Antimicrobial Agents and Chemotherapy Karl Drlica, The Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey.
988			_aSpringer_Medicine_2018
650		7	_aResistencia a los medicamentos _2embne _9146972
700	1		_aFong, I. W. _q(Ignatius W.) _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/27319215 _988388
700	1		_aShlaes, David _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/149352489
700	1		_aDrlica, Karl _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n82243427 _1http://viaf.org/viaf/79115831 _963977
776	0	8	_iPrinted edition: _z9783319785370
776	0	8	_iPrinted edition: _z9783319785394
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-78538-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _b06/2019 _cm _dz _ea _feng _ggw _h0